

Edgar Filing: JOHNSON & JOHNSON - Form 8-K

JOHNSON & JOHNSON
Form 8-K
April 05, 2004

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8K

Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 30,
2003

JOHNSON & JOHNSON

(Exact name of registrant as specified in its charter)

New Jersey	1-3215	22-1024240
(State or other jurisdiction of incorporation)	Commission File Number)	(I.R.S. Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of principal executive offices) (zip code)

Registrant's telephone number including area code: (732) 524-0400
Item 5. Other Events.

On April 2, 2004, Cordis Cardiology, a Division of Cordis Corporation, a Johnson & Johnson company, issued a press Release reporting that it received a warning letter from the U.S. Food and Drug Administration (FDA) regarding FDA's observations concerning the Good Manufacturing Practice (GMP) regulations.

Exhibit No.	Description of Exhibit
99.17	Press Release dated April 2, 2004.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Edgar Filing: JOHNSON & JOHNSON - Form 8-K

JOHNSON & JOHNSON

Date: April 5, 2004

By: /s/ Michael H. Ullmann
Michael H. Ullmann
Corporate Secretary